Zobrazeno 1 - 10
of 744
pro vyhledávání: '"Toshio Shimizu"'
Autor:
Toshio Shimizu, John Powderly, Albiruni Abdul Razak, Patricia LoRusso, Kathy D. Miller, Steven Kao, Sarah Kongpachith, Catherine Tribouley, Michelle Graham, Brian Stoll, Maulik Patel, Mohammad Sahtout, Martha Blaney, Rachel Leibman, Talia Golan, Anthony Tolcher
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundTransforming growth factor (TGF)-ß1 is a pleiotropic cytokine that can promote tumor growth and suppress antitumor immune responses. Latent TGF-ß1 associates with glycoprotein-A repetition predominant (GARP) on the surface of regulatory T
Externí odkaz:
https://doaj.org/article/ecaf119bc00648e1807c616981421d5c
Autor:
Toshiaki Takakura, Hiroaki Akamatsu, Atsushi Washioka, Eriko Murakami, Ryota Shibaki, Toshio Shimizu, Yasuhiro Koh, Nobuyuki Yamamoto
Publikováno v:
Respirology Case Reports, Vol 12, Iss 9, Pp n/a-n/a (2024)
Abstract Several predictive factors of immune checkpoint inhibitor response have been reported, but there has not been sufficient exploration of which patients benefit from immune checkpoint inhibitor rechallenge. We report the case of a patient with
Externí odkaz:
https://doaj.org/article/0ae7b666526f4947868c9ccb401342a5
Autor:
Yasutoshi Kuboki, Takafumi Koyama, Nobuaki Matsubara, Yoichi Naito, Shunsuke Kondo, Kenichi Harano, Kan Yonemori, Kiyotaka Yoh, Yuan Gu, Tetsuya Mita, Xuejun Chen, Eiji Ueda, Noboru Yamamoto, Toshihiko Doi, Toshio Shimizu
Publikováno v:
Cancer Medicine, Vol 13, Iss 8, Pp n/a-n/a (2024)
Abstract Background Retifanlimab is a humanized monoclonal antibody targeting programmed death protein‐1, and INCB001158 is an oral arginase inhibitor. This phase Ib study investigated retifanlimab, INCB001158, and their combination in Japanese pat
Externí odkaz:
https://doaj.org/article/054b73aa0e9c4d059dd35a08e6fa57cd
Publikováno v:
Radiology Case Reports, Vol 18, Iss 9, Pp 2975-2977 (2023)
We encountered a case of multiple system atrophy parkinsonian subtype (MSA-P) with right-dominant parkinsonism in the early stage of the disease. Atrophy of the posterolateral putamen and iron deposition are the neuropathological hallmark of MSA-P. C
Externí odkaz:
https://doaj.org/article/e3e7492735434aaa93f41d4f2ecd19fd
Autor:
Yutaka Fujiwara, Yasutoshi Kuboki, Masayuki Furukawa, Nobumasa Mizuno, Hiroki Hara, Tatsuya Ioka, Makoto Ueno, Yasuo Takahashi, Shunji Takahashi, Shinji Takeuchi, Christine Lihou, Tao Ji, Chenwei Tian, Toshio Shimizu
Publikováno v:
Cancer Medicine, Vol 12, Iss 9, Pp 10597-10611 (2023)
Abstract Background FIGHT‐102 was a phase 1, dose‐escalation, dose‐expansion study of pemigatinib in Japanese patients with advanced solid tumors. Here, we report safety, tolerability, and preliminary efficacy of pemigatinib from FIGHT‐102. M
Externí odkaz:
https://doaj.org/article/9baedb4c4d12487081450e5da764609a
Autor:
Kentaro Kawama, Rui Shimazaki, Yoko Sunami, Natsuki Miyakoshi, Shinsuke Tobisawa, Toshio Shimizu, Kazushi Takahashi
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
Coronavirus Disease 2019 (COVID-19) is known to have various, neurological manifestations. We herein report three patients with MRI-negative myelitis following COVID-19 with abnormal somatosensory evoked potentials (SEPs). Decreased amplitude of the
Externí odkaz:
https://doaj.org/article/3f5e20feb0524c019b33b9c747786f62
Publikováno v:
Brain Sciences, Vol 13, Iss 9, p 1325 (2023)
Cortical responses in somatosensory evoked potentials (SEP) are enhanced in patients with amyotrophic lateral sclerosis (ALS). This study investigated whether sensory gating is involved in the pathophysiology of sensory cortical hyperactivity in ALS
Externí odkaz:
https://doaj.org/article/4bde97f8fd994967928c2640aa0880ed
Autor:
Makoto Nishino, Maiko Fujimori, Takafumi Koyama, Makoto Hirata, Noriko Tanabe, Toshio Shimizu, Noboru Yamamoto, Yosuke Uchitomi
Publikováno v:
PLoS ONE, Vol 18, Iss 5, p e0283968 (2023)
Precision medicine is rapidly changing the diagnostic and treatment spectrum of oncology. In May 2019, comprehensive genomic profiling (CGP) (somatic and/or germline) was approved for reimbursement in Japan. While the promise of novel and targeted th
Externí odkaz:
https://doaj.org/article/ea3900362ae049a4aec01f52771fe6e2
Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer
Autor:
Ikuko Takeda Nakamura, Shinji Kohsaka, Masachika Ikegami, Hiroshi Ikeuchi, Toshihide Ueno, Kunhua Li, Tyler S. Beyett, Takafumi Koyama, Toshio Shimizu, Noboru Yamamoto, Fumiyuki Takahashi, Kazuhisa Takahashi, Michael J. Eck, Hiroyuki Mano
Publikováno v:
npj Precision Oncology, Vol 5, Iss 1, Pp 1-14 (2021)
Abstract Various genetic alterations of the fibroblast growth factor receptor (FGFR) family have been detected across a wide range of cancers. However, inhibition of FGFR signaling by kinase inhibitors demonstrated limited clinical effectiveness. Her
Externí odkaz:
https://doaj.org/article/1eb0d4f54965435d896fb494c2235251
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Non-small cell lung cancer (NSCLC), one of the deadliest types of cancers worldwide, has been the target of immunotherapy due to its high immune antigenicity. With the addition of immune-checkpoint inhibitors (ICIs), including anti-PD-1/PD-L1 antibod
Externí odkaz:
https://doaj.org/article/9e9aa9d479eb41f89c2842574a3d8d16